| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu 874-0838, Japan [M. M., T. S., H. I.]; Department of Surgery, Saitama Cancer Center, Saitama 362-0806, Japan [Y. T.]; Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan [K. S.]; and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [K. M., H. A., K. H., C. M. C.]
The FHIT gene, located at chromosome 3p14.2, is a tumor suppressor gene often involved in tumors resulting from exposure to environmental carcinogens. We studied 46 pairs of esophageal primary tumors and corresponding normal squamous mucosa specimens by molecular genetic and immunohistochemical methods to investigate the role of the FHIT gene in esophageal carcinoma. In addition, we studied several different types of lesions, such as carcinoma in situ or dysplasia by immunohistochemistry. Loss of heterozygosity at or around the FHIT gene was observed in 35 (76%) primary tumors. Immunohistochemical detection of Fhit protein in the primary tumors demonstrated that 14 (30%) were positive and 32 (70%) were negative. We observed concordance between loss of Fhit protein and loss of heterozygosity and between loss of Fhit protein and RNA abnormalities. Because the FHIT/FRA3B locus is susceptible to damage by environmental carcinogens, we investigated the correlation between Fhit expression and smoking or alcohol habits. In this relatively small study, the patients who were both heavy users of tobacco and alcohol showed a significantly higher frequency of loss of Fhit expression than those who were light users. Noncarcinomatous squamous epithelium showed positive Fhit reactivity in most cases; however, five showed negative Fhit reactivity. Interestingly, all of these five patients had habits of heavy use of tobacco and alcohol. Eight of 12 carcinomas in situ, 2 of 4 severe dysplasias, 4 of 8 moderate dysplasias, and 3 of 9 mild dysplastic lesions showed negative Fhit reactivity. These findings indicated that loss of Fhit expression may be an early event in the development of human esophageal carcinoma and may occur even in normal-appearing squamous epithelium in some patients heavily exposed to environmental carcinogens.
This article has been cited by other articles:
![]() |
H. Zhang, Y.-J. Hou, S.-Y. Han, E. C. Zhang, K. Huebner, and J. Zhang Mammalian nitrilase 1 homologue Nit1 is a negative regulator in T cells Int. Immunol., June 1, 2009; 21(6): 691 - 703. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. De Flora, F. D'Agostini, A. Izzotti, N. Zanesi, C. M. Croce, and R. Balansky Molecular and Cytogenetical Alterations Induced by Environmental Cigarette Smoke in Mice Heterozygous for Fhit Cancer Res., February 1, 2007; 67(3): 1001 - 1006. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bavi, Z. Jehan, V. Atizado, H. Al-Dossari, F. Al-Dayel, A. Tulbah, S. S. Amr, S. S. Sheikh, A. Ezzat, H. El-Solh, et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1708 - 1718. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okumura, S. Tsunoda, Y. Mori, T. Ito, K. Kikuchi, T. C. Wang, S. Yasumoto, and Y. Shimada The Biological Role of the Low-Affinity p75 Neurotrophin Receptor in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., September 1, 2006; 12(17): 5096 - 5103. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Tzao, G.-H. Sun, H.-J. Tung, H.-S. Hsu, W.-H. Hsu, Y.-C. Wang, Y.-L. Cheng, and S.-C. Lee Reduced Acetylated Histone H4 is Associated With Promoter Methylation of the Fragile Histidine Triad Gene in Resected Esophageal Squamous Cell Carcinoma Ann. Thorac. Surg., August 1, 2006; 82(2): 396 - 401. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mimori, H. Ishii, H. Nagahara, T. Sudo, K. Yamashita, H. Inoue, G. F. Barnard, and M. Mori FHIT Is Up-Regulated by Inflammatory Stimuli and Inhibits Prostaglandin E2-Mediated Cancer Progression. Cancer Res., March 1, 2006; 66(5): 2683 - 2690. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-K. Tai, J. I. Lee, K. K. Ang, A. K. El-Naggar, K. A. Hassan, D. Liu, J. J. Lee, H. Ren, W. K. Hong, and L. Mao Loss of Fhit Expression in Head and Neck Squamous Cell Carcinoma and Its Potential Clinical Implication Clin. Cancer Res., August 15, 2004; 10(16): 5554 - 5557. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kuroki, S. Yendamuri, F. Trapasso, A. Matsuyama, R. I. Aqeilan, H. Alder, S. Rattan, R. Cesari, M. L. Nolli, N. N. Williams, et al. The Tumor Suppressor Gene WWOX at FRA16D Is Involved in Pancreatic Carcinogenesis Clin. Cancer Res., April 1, 2004; 10(7): 2459 - 2465. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kuroki, F. Trapasso, S. Yendamuri, A. Matsuyama, H. Alder, M. Mori, and C. M. Croce Allele Loss and Promoter Hypermethylation of VHL, RAR-{beta}, RASSF1A, and FHIT Tumor Suppressor Genes on Chromosome 3p in Esophageal Squamous Cell Carcinoma Cancer Res., July 1, 2003; 63(13): 3724 - 3728. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kuroki, F. Trapasso, S. Yendamuri, A. Matsuyama, H. Alder, N. N. Williams, L. R. Kaiser, and C. M. Croce Allelic Loss on Chromosome 3p21.3 and Promoter Hypermethylation of Semaphorin 3B in Non-Small Cell Lung Cancer Cancer Res., June 15, 2003; 63(12): 3352 - 3355. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kuroki, F. Trapasso, S. Yendamuri, A. Matsuyama, H. Alder, M. Mori, and C. M. Croce Promoter Hypermethylation of RASSF1A in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., April 1, 2003; 9(4): 1441 - 1445. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yendamuri, T. Kuroki, F. Trapasso, A. C. Henry, K. R. Dumon, K. Huebner, N. N. Williams, L. R. Kaiser, and C. M. Croce WW Domain Containing Oxidoreductase Gene Expression Is Altered in Non-Small Cell Lung Cancer Cancer Res., February 15, 2003; 63(4): 878 - 881. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Park, S. Schulz, J. Haaf, J. C. Kairys, and S. A. Waldman Ectopic Expression of Guanylyl Cyclase C in Adenocarcinomas of the Esophagus and Stomach Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 739 - 744. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kuroki, F. Trapasso, T. Shiraishi, H. Alder, K. Mimori, M. Mori, and C. M. Croce Genetic Alterations of the Tumor Suppressor Gene WWOX in Esophageal Squamous Cell Carcinoma Cancer Res., April 1, 2002; 62(8): 2258 - 2260. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Roz, M. Gramegna, H. Ishii, C. M. Croce, and G. Sozzi Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines PNAS, March 19, 2002; 99(6): 3615 - 3620. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Kraggerud, P. Aman, R. Holm, A. E. Stenwig, S. D. Fossa, J. M. Nesland, and R. A. Lothe Alterations of the Fragile Histidine Triad Gene, FHIT, and Its Encoded Products Contribute to Testicular Germ Cell Tumorigenesis Cancer Res., January 1, 2002; 62(2): 512 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies JAMA, November 21, 2001; 286(19): 2441 - 2449. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mori, K. Mimori, T. Masuda, K. Yoshinaga, K. Yamashita, A. Matsuyama, and H. Inoue Absence of Msh2 Protein Expression Is Associated with Alteration in the FHIT Locus and Fhit Protein Expression in Colorectal Carcinoma Cancer Res., October 1, 2001; 61(20): 7379 - 7382. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shiraishi, T. Druck, K. Mimori, J. Flomenberg, L. Berk, H. Alder, W. Miller, K. Huebner, and C. M. Croce Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit PNAS, April 18, 2001; (2001) 91095898. [Abstract] [Full Text] |
||||
![]() |
K. R. Dumon, H. Ishii, L. Y. Y. Fong, N. Zanesi, V. Fidanza, R. Mancini, A. Vecchione, R. Baffa, F. Trapasso, M. J. During, et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice PNAS, February 22, 2001; (2001) 61020098. [Abstract] [Full Text] |
||||
![]() |
J. I. Lee, J.-C. Soria, K. Hassan, D. Liu, X. Tang, A. El-Naggar, W. K. Hong, and L. Mao Loss of Fhit Expression Is a Predictor of Poor Outcome in Tongue Cancer Cancer Res., February 1, 2001; 61(3): 837 - 841. [Abstract] [Full Text] |
||||
![]() |
H. Ishii, K. R. Dumon, A. Vecchione, F. Trapasso, K. Mimori, H. Alder, M. Mori, G. Sozzi, R. Baffa, K. Huebner, et al. Effect of Adenoviral Transduction of the Fragile Histidine Triad Gene into Esophageal Cancer Cells Cancer Res., February 1, 2001; 61(4): 1578 - 1584. [Abstract] [Full Text] |
||||
![]() |
D. C. Connolly, D. L. Greenspan, R. Wu, X. Ren, R. L. Dunn, K. V. Shah, R. W. Jones, F. X. Bosch, N. Muñoz, and K. R. Cho Loss of Fhit Expression in Invasive Cervical Carcinomas and Intraepithelial Lesions Associated with Invasive Disease Clin. Cancer Res., September 1, 2000; 6(9): 3505 - 3510. [Abstract] [Full Text] |
||||
![]() |
K. R. Dumon, H. Ishii, L. Y. Y. Fong, N. Zanesi, V. Fidanza, R. Mancini, A. Vecchione, R. Baffa, F. Trapasso, M. J. During, et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice PNAS, March 13, 2001; 98(6): 3346 - 3351. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shiraishi, T. Druck, K. Mimori, J. Flomenberg, L. Berk, H. Alder, W. Miller, K. Huebner, and C. M. Croce Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit PNAS, May 8, 2001; 98(10): 5722 - 5727. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |